In Brief

Jury orders McNeil to pay $63M in TEN suit; Marshals seize Globe All Wellness products; USP forms supplement adulteration panel; FDA warnings for GMPs flow; Hurricane Sandy impact knocks GNC revenue; Icahn takes Herbalife stake; U.K. shuts down melatonin ad.

A Massachusetts jury Feb. 13 ordered McNeil-PPC Inc. to pay $63 million to the family of a teenager who suffered toxic epidermal necrolysis after taking Children’s Motrin when she was 7 years old. The amount could exceed $109 million after factoring in a 12% annual interest rate since the case was filed, said a paralegal with the law firm that represented the family. The lawsuit filed in January 2007 against McNeil and parent company Johnson & Johnson alleges the firms were grossly negligent for failing to warn about the known risk of TEN in a manner that consumers could understand. A package insert w the ibuprofen product warns of a less than 1% “probable causal relationship” of developing TEN, according to the suit. A J&J/McNeil spokeswoman said the firm “sympathizes deeply” with the family, which “has suffered a tragedy.” She said TEN is “a very rare condition” and Children’s Motrin when used as directed is safe and effective. J&J has faced similar lawsuits with mixed results, including a case in 2011 in which a jury awarded $10 million to a 13-year-old and her family after she suffered a similar reaction to Children’s Motrin Also see "In Brief" - Pink Sheet, 30 May, 2011..

U.S. Marshals seized dietary supplements tainted with the prescription weight-loss ingredient sibutramine from [Globe All Wellness LLC]at the behest of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.

EU Pharma Overhaul May Reshape Aspects Of Drug Promotion And HCP Partnerships

 

Lawyers explain how changes to rules around drug advertising and promotional activities under the EU pharma reform package could impact companies operating in the bloc, with one legal expert advising companies to “monitor developments closely.”

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By 

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

More from Compliance

Big PBM Dominance Enabled By Affiliated Third Party Administrators Limiting Choices, FTC Told

 
• By 

Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.

EU 15% Tariff Deal Still Leaves Questions For Pharma On Possible Grace Period, Generic Exemption

 

While the 15% rate is a substantial blow for pharmaceutical firms, the US-EU deal provides a framework for trade agreements with other countries that could see the industry avoiding higher tariffs elsewhere.

No Surprise Here: Foreign Drug Facilities Should Expect Surprise Inspections, US FDA Says

 
• By 

The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.